Biogen (BUE:BIIB) Other Current Payables : ARS0 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Biogen Other Current Payables?

Biogen's Other Current Payables for the quarter that ended in Mar. 2024 was ARS0 Mil.

Biogen's quarterly Other Current Payables declined from Sep. 2023 (ARS0 Mil) to Dec. 2023 (ARS0 Mil) but then increased from Dec. 2023 (ARS0 Mil) to Mar. 2024 (ARS0 Mil).

Biogen's annual Other Current Payables increased from Dec. 2021 (ARS-0 Mil) to Dec. 2022 (ARS0 Mil) and increased from Dec. 2022 (ARS0 Mil) to Dec. 2023 (ARS0 Mil).

Biogen Other Current Payables Historical Data

The historical data trend for Biogen's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Other Current Payables Chart

Biogen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Current Payables

Get a 7-Day Free Trial

Biogen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Current Payables	Get a 7-Day Free Trial															-	-	-	-	-

Biogen Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Biogen Other Current Payables Related Terms

Thank you for viewing the detailed overview of Biogen's Other Current Payables provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (BUE:BIIB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BUE:BIIB) » Definitions » Other Current Payables

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico 1BIIB:Italy IDP:Germany BIIB34:Brazil BIIB:Austria

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.